Location of theMT-ATP8 gene in the human mitochondrial genome.MT-ATP8 is one of the two ATP synthase mitochondrial genes (red boxes).The 46-nucleotide overlap in the reading frames of the human mitochondrial genesMT-ATP8 andMT-ATP6. For each nucleotide triplet (square brackets), the corresponding amino acid is given (one-letter code), either in the +1 frame forMT-ATP8 (in red) or in the +3 frame forMT-ATP6 (in blue).
MT-ATP8 (orATP8) is amitochondrial gene with the full name 'mitochondrially encoded ATP synthase membrane subunit 8' that encodes a subunit ofmitochondrial ATP synthase,ATP synthase Fo subunit 8 (orsubunit A6L). This subunit belongs to the Fo complex of the large, transmembrane F-typeATP synthase.[5] This enzyme, which is also known as complex V, is responsible for the final step ofoxidative phosphorylation in theelectron transport chain. Specifically, one segment of ATP synthase allows positively chargedions, calledprotons, to flow across a specialized membrane inside mitochondria. Another segment of the enzyme uses the energy created by this proton flow to convert a molecule calledadenosine diphosphate (ADP) toATP.[6] Subunit 8 differs insequence betweenMetazoa,plants andFungi.
The ATP synthase protein 8 of human and other mammals is encoded in themitochondrial genome by theMT-ATP8gene. When the complete human mitochondrial genome was first published, theMT-ATP8 gene was described as the unidentifiedreading frameURF A6L.[5] An unusual feature of theMT-ATP8 gene is its 46-nucleotide overlap with theMT-ATP6 gene. With respect to the reading frame (+1) ofMT-ATP8, theMT-ATP6 gene starts on the +3 reading frame.
The MT-ATP8 protein weighs 8 kDa and is composed of 68amino acids.[7][8] The protein is a subunit of the F1Fo ATPase, also known asComplex V, which consists of 14 nuclear- and 2 mitochondrial-encoded subunits. F-type ATPases consist of two structural domains, F1 containing the extramembraneous catalytic core and Fo containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. As an A subunit, MT-ATP8 is contained within the non-catalytic,transmembrane Fo portion of the complex, comprising theproton channel. The catalytic portion of mitochondrial ATP synthase consists of 5 different subunits (alpha, beta, gamma, delta, and epsilon) assembled with a stoichiometry of 3 alpha, 3 beta, and a single representative of the other 3. The proton channel consists of three main subunits (a, b, c). This gene encodes the delta subunit of the catalytic core. Alternatively spliced transcript variants encoding the same isoform have been identified.[9][6]
Thisprotein subunit appears to be an integral component of the stator stalk inyeastmitochondrialF-ATPases.[11] The stator stalk is anchored in themembrane, and acts to prevent futile rotation of the ATPase subunits relative to the rotor during coupled ATP synthesis/hydrolysis. This subunit may have an analogous function inMetazoa.
Thenomenclature of the enzyme has a long history. The F1 fraction derives its name from the term "Fraction 1" and Fo (written as a subscript letter "o", not "zero") derives its name from being the binding fraction foroligomycin, a type of naturally-derived antibiotic that is able to inhibit the Fo unit of ATP synthase.[12][13] The Fo region of ATP synthase is a proton pore that is embedded in the mitochondrial membrane. It consists of three main subunits A, B, and C, and (in humans) six additional subunits,d,e,f,g,MT-ATP6 (or F6), and MT-ATP8 (or A6L). 3D structure ofE. coli homologue of this subunit was modeled based onelectron microscopy data (chain M ofPDB:1c17). It forms a transmembrane 4-α-bundle.
Mutations to MT-ATP8 and other genes affectingoxidative phosphorylation in the mitochondria have been associated with a variety ofneurodegenerative andcardiovascular disorders, including mitochondrial complex V deficiency,Leber's hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy with stroke-like episodes (MELAS),Leigh syndrome, andNARP syndrome. Most of the body's cells contain thousands of mitochondria, each with one or more copies ofmitochondrial DNA. The severity of somemitochondrial disorders is associated with the percentage of mitochondria in each cell that has a particular genetic change. People withLeigh syndrome due to a MT-ATP6 gene mutation tend to have a very high percentage of mitochondria with the mutation (from more than 90 percent to 95 percent). The less-severe features ofNARP result from a lower percentage of mitochondria with the mutation, typically 70 percent to 90 percent. Because these two conditions result from the same genetic changes and can occur in different members of a single family, researchers believe that they may represent a spectrum of overlapping features instead of two distinct syndromes.[6]
Mitochondrial complex V deficiency presents with heterogeneous clinical manifestations includingneuropathy,ataxia,hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy can present with negligible to extremehypertrophy, minimal to extensivefibrosis andmyocyte disarray, absent to severe left ventricular outflow tract obstruction, and distinct septal contours/morphologies with extremely varying clinical course.[14][15]
Mitochondrial complex V deficiency is a shortage (deficiency) or loss of function incomplex V of theelectron transport chain that can cause a wide variety ofsigns and symptoms affecting many organs and systems of the body, particularly thenervous system and theheart. The disorder can be life-threatening in infancy or early childhood. Affected individuals may have feeding problems, slow growth, low muscle tone (hypotonia), extreme fatigue (lethargy), anddevelopmental delay. They tend to develop elevated levels oflactic acid in the blood (lactic acidosis), which can cause nausea, vomiting, weakness, and rapid breathing. High levels ofammonia in the blood (hyperammonemia) can also occur in affected individuals, and in some cases result in abnormal brain function (encephalopathy) and damage to other organs.[16]Ataxia,microcephaly, developmental delay and intellectual disability have been observed in patients with a frameshift mutation in MT-ATP6. This causes a C insertion at position 8612 that results in a truncated protein only 36 amino acids long, and two T > Csingle-nucleotide polymorphisms at positions 8610 and 8614 that result in a homopolymericcytosine stretch.[17]
Hypertrophic cardiomyopathy, a common feature of mitochondrial complex V deficiency, is characterized by thickening (hypertrophy) of thecardiac muscle that can lead toheart failure.[16] The m.8528T>C mutation occurs in the overlapping region of the MT-ATP6 and MT-ATP8 genes and has been described in multiple patients with infantile cardiomyopathy. This mutation changes the initiation codon in MT-ATP6 tothreonine as well as a change fromtryptophan toarginine at position 55 of MT-ATP8.[18][15] Individuals with mitochondrial complex V deficiency may also have a characteristic pattern of facial features, including a high forehead, curved eyebrows, outside corners of the eyes that point downward (downslantingpalpebral fissures), a prominent bridge of the nose, low-set ears, thin lips, and a small chin (micrognathia).[16]
^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^abAnderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG (April 1981). "Sequence and organization of the human mitochondrial genome".Nature.290 (5806):457–65.Bibcode:1981Natur.290..457A.doi:10.1038/290457a0.PMID7219534.S2CID4355527.
^Velours J, Paumard P, Soubannier V, Spannagel C, Vaillier J, Arselin G, Graves PV (May 2000). "Organisation of the yeast ATP synthase F(0):a study based on cysteine mutants, thiol modification and cross-linking reagents".Biochimica et Biophysica Acta (BBA) - Bioenergetics.1458 (2–3):443–56.doi:10.1016/S0005-2728(00)00093-1.PMID10838057.
^abcWare SM, El-Hassan N, Kahler SG, Zhang Q, Ma YW, Miller E, Wong B, Spicer RL, Craigen WJ, Kozel BA, Grange DK, Wong LJ (May 2009). "Infantile cardiomyopathy caused by a mutation in the overlapping region of mitochondrial ATPase 6 and 8 genes".Journal of Medical Genetics.46 (5):308–14.doi:10.1136/jmg.2008.063149.PMID19188198.S2CID25354118.
^Jackson CB, Hahn D, Schröter B, Richter U, Battersby BJ, Schmitt-Mechelke T, Marttinen P, Nuoffer JM, Schaller A (June 2017). "A novel mitochondrial ATP6 frameshift mutation causing isolated complex V deficiency, ataxia and encephalomyopathy".European Journal of Medical Genetics.60 (6):345–351.doi:10.1016/j.ejmg.2017.04.006.hdl:10138/237062.PMID28412374.
^Imai A, Fujita S, Kishita Y, Kohda M, Tokuzawa Y, Hirata T, Mizuno Y, Harashima H, Nakaya A, Sakata Y, Takeda A, Mori M, Murayama K, Ohtake A, Okazaki Y (March 2016). "Rapidly progressive infantile cardiomyopathy with mitochondrial respiratory chain complex V deficiency due to loss of ATPase 6 and 8 protein".International Journal of Cardiology.207:203–5.doi:10.1016/j.ijcard.2016.01.026.PMID26803244.
Torroni A, Achilli A, Macaulay V, Richards M, Bandelt HJ (June 2006). "Harvesting the fruit of the human mtDNA tree".Trends in Genetics.22 (6):339–45.doi:10.1016/j.tig.2006.04.001.PMID16678300.
Bodenteich A, Mitchell LG, Polymeropoulos MH, Merril CR (May 1992). "Dinucleotide repeat in the human mitochondrial D-loop".Human Molecular Genetics.1 (2): 140.doi:10.1093/hmg/1.2.140-a.PMID1301157.
Lu X, Walker T, MacManus JP, Seligy VL (July 1992). "Differentiation of HT-29 human colonic adenocarcinoma cells correlates with increased expression of mitochondrial RNA: effects of trehalose on cell growth and maturation".Cancer Research.52 (13):3718–25.PMID1377597.
Marzuki S, Noer AS, Lertrit P, Thyagarajan D, Kapsa R, Utthanaphol P, Byrne E (December 1991). "Normal variants of human mitochondrial DNA and translation products: the building of a reference data base".Human Genetics.88 (2):139–45.doi:10.1007/bf00206061.PMID1757091.S2CID28048453.
Attardi G, Chomyn A, Doolittle RF, Mariottini P, Ragan CI (1987). "Seven unidentified reading frames of human mitochondrial DNA encode subunits of the respiratory chain NADH dehydrogenase".Cold Spring Harbor Symposia on Quantitative Biology. 51 Pt 1 (1):103–14.doi:10.1101/sqb.1986.051.01.013.PMID3472707.
Chomyn A, Cleeter MW, Ragan CI, Riley M, Doolittle RF, Attardi G (October 1986). "URF6, last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit".Science.234 (4776):614–8.Bibcode:1986Sci...234..614C.doi:10.1126/science.3764430.PMID3764430.
Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G (1985). "Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase".Nature.314 (6012):592–7.Bibcode:1985Natur.314..592C.doi:10.1038/314592a0.PMID3921850.S2CID32964006.
Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG (April 1981). "Sequence and organization of the human mitochondrial genome".Nature.290 (5806):457–65.Bibcode:1981Natur.290..457A.doi:10.1038/290457a0.PMID7219534.S2CID4355527.